The European Vasculitis Society 2016 Meeting Report

Research output: Contribution to journalArticle

Standard

The European Vasculitis Society 2016 Meeting Report. / Bajema, Ingeborg M.; Bruijn, Jan A.; Casian, Alina; Cid, Maria C.; Csernok, Elena; Van Daalen, Emma; Harper, Lorraine; Hauser, Thomas; Little, Mark A.; Luqmani, Raashid A.; Mahr, Alfred; Ponte, Cristina; Salama, Alan; Segelmark, Mårten; Suzuki, Kazuo; Sznajd, Jan; Teng, Y.k. Onno; Vaglio, Augusto; Westman, Kerstin; Jayne, David.

In: Kidney International Reports, Vol. 2, No. 6, 11.2017, p. 1018-1031.

Research output: Contribution to journalArticle

Harvard

Bajema, IM, Bruijn, JA, Casian, A, Cid, MC, Csernok, E, Van Daalen, E, Harper, L, Hauser, T, Little, MA, Luqmani, RA, Mahr, A, Ponte, C, Salama, A, Segelmark, M, Suzuki, K, Sznajd, J, Teng, YKO, Vaglio, A, Westman, K & Jayne, D 2017, 'The European Vasculitis Society 2016 Meeting Report', Kidney International Reports, vol. 2, no. 6, pp. 1018-1031. https://doi.org/10.1016/j.ekir.2017.09.008

APA

Bajema, I. M., Bruijn, J. A., Casian, A., Cid, M. C., Csernok, E., Van Daalen, E., Harper, L., Hauser, T., Little, M. A., Luqmani, R. A., Mahr, A., Ponte, C., Salama, A., Segelmark, M., Suzuki, K., Sznajd, J., Teng, Y. K. O., Vaglio, A., Westman, K., & Jayne, D. (2017). The European Vasculitis Society 2016 Meeting Report. Kidney International Reports, 2(6), 1018-1031. https://doi.org/10.1016/j.ekir.2017.09.008

Vancouver

Bajema IM, Bruijn JA, Casian A, Cid MC, Csernok E, Van Daalen E et al. The European Vasculitis Society 2016 Meeting Report. Kidney International Reports. 2017 Nov;2(6):1018-1031. https://doi.org/10.1016/j.ekir.2017.09.008

Author

Bajema, Ingeborg M. ; Bruijn, Jan A. ; Casian, Alina ; Cid, Maria C. ; Csernok, Elena ; Van Daalen, Emma ; Harper, Lorraine ; Hauser, Thomas ; Little, Mark A. ; Luqmani, Raashid A. ; Mahr, Alfred ; Ponte, Cristina ; Salama, Alan ; Segelmark, Mårten ; Suzuki, Kazuo ; Sznajd, Jan ; Teng, Y.k. Onno ; Vaglio, Augusto ; Westman, Kerstin ; Jayne, David. / The European Vasculitis Society 2016 Meeting Report. In: Kidney International Reports. 2017 ; Vol. 2, No. 6. pp. 1018-1031.

Bibtex

@article{ee2e2d4f9e2846b59e5d3648d5b4dc8e,
title = "The European Vasculitis Society 2016 Meeting Report",
abstract = "The 2016 European Vasculitis Society (EUVAS) meeting, held in Leiden, the Netherlands, was centered around phenotypic subtyping in antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV). There were parallel meetings of the EUVAS petals, which here report on disease assessment; database; and long-term follow-up, registries, genetics, histology, biomarker studies, and clinical trials. Studies currently conducted will improve our ability to discriminate between different forms of vasculitis. In a project that involves the 10-year follow-up of AAV patients, we are working on retrieving data on patient and renal survival, relapse rate, the cumulative incidence of malignancies, and comorbidities. Across Europe, several vasculitis registries were developed covering over 10,000 registered patients. In the near future, these registries will facilitate clinical research in AAV on a scale hitherto unknown. Current studies on the genetic background of AAV will explore the potential prognostic significance of genetic markers and further refine genetic associations with distinct disease subsets. The histopathological classification of ANCA-associated glomerulonephritis is currently evaluated in light of data coming out of a large international validation study. In our continuous search for biomarkers to predict clinical outcome, promising new markers are important subjects of current research. Over the last 2 decades, a host of clinical trials have provided evidence for refinement of therapeutic regimens. We give an overview of clinical trials currently under development, and consider refractory vasculitis in detail. The goal of EUVAS is to stimulate ongoing research in clinical, serological, and histological management and techniques for patients with systemic vasculitis, with an outlook on the applicability for clinical trials.",
keywords = "ANCA , renal outcome , therapy , vasculitis",
author = "Bajema, {Ingeborg M.} and Bruijn, {Jan A.} and Alina Casian and Cid, {Maria C.} and Elena Csernok and {Van Daalen}, Emma and Lorraine Harper and Thomas Hauser and Little, {Mark A.} and Luqmani, {Raashid A.} and Alfred Mahr and Cristina Ponte and Alan Salama and M{\aa}rten Segelmark and Kazuo Suzuki and Jan Sznajd and Teng, {Y.k. Onno} and Augusto Vaglio and Kerstin Westman and David Jayne",
year = "2017",
month = nov
doi = "10.1016/j.ekir.2017.09.008",
language = "English",
volume = "2",
pages = "1018--1031",
journal = "Kidney International Reports",
issn = "2468-0249",
publisher = "Elsevier",
number = "6",

}

RIS

TY - JOUR

T1 - The European Vasculitis Society 2016 Meeting Report

AU - Bajema, Ingeborg M.

AU - Bruijn, Jan A.

AU - Casian, Alina

AU - Cid, Maria C.

AU - Csernok, Elena

AU - Van Daalen, Emma

AU - Harper, Lorraine

AU - Hauser, Thomas

AU - Little, Mark A.

AU - Luqmani, Raashid A.

AU - Mahr, Alfred

AU - Ponte, Cristina

AU - Salama, Alan

AU - Segelmark, Mårten

AU - Suzuki, Kazuo

AU - Sznajd, Jan

AU - Teng, Y.k. Onno

AU - Vaglio, Augusto

AU - Westman, Kerstin

AU - Jayne, David

PY - 2017/11

Y1 - 2017/11

N2 - The 2016 European Vasculitis Society (EUVAS) meeting, held in Leiden, the Netherlands, was centered around phenotypic subtyping in antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV). There were parallel meetings of the EUVAS petals, which here report on disease assessment; database; and long-term follow-up, registries, genetics, histology, biomarker studies, and clinical trials. Studies currently conducted will improve our ability to discriminate between different forms of vasculitis. In a project that involves the 10-year follow-up of AAV patients, we are working on retrieving data on patient and renal survival, relapse rate, the cumulative incidence of malignancies, and comorbidities. Across Europe, several vasculitis registries were developed covering over 10,000 registered patients. In the near future, these registries will facilitate clinical research in AAV on a scale hitherto unknown. Current studies on the genetic background of AAV will explore the potential prognostic significance of genetic markers and further refine genetic associations with distinct disease subsets. The histopathological classification of ANCA-associated glomerulonephritis is currently evaluated in light of data coming out of a large international validation study. In our continuous search for biomarkers to predict clinical outcome, promising new markers are important subjects of current research. Over the last 2 decades, a host of clinical trials have provided evidence for refinement of therapeutic regimens. We give an overview of clinical trials currently under development, and consider refractory vasculitis in detail. The goal of EUVAS is to stimulate ongoing research in clinical, serological, and histological management and techniques for patients with systemic vasculitis, with an outlook on the applicability for clinical trials.

AB - The 2016 European Vasculitis Society (EUVAS) meeting, held in Leiden, the Netherlands, was centered around phenotypic subtyping in antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV). There were parallel meetings of the EUVAS petals, which here report on disease assessment; database; and long-term follow-up, registries, genetics, histology, biomarker studies, and clinical trials. Studies currently conducted will improve our ability to discriminate between different forms of vasculitis. In a project that involves the 10-year follow-up of AAV patients, we are working on retrieving data on patient and renal survival, relapse rate, the cumulative incidence of malignancies, and comorbidities. Across Europe, several vasculitis registries were developed covering over 10,000 registered patients. In the near future, these registries will facilitate clinical research in AAV on a scale hitherto unknown. Current studies on the genetic background of AAV will explore the potential prognostic significance of genetic markers and further refine genetic associations with distinct disease subsets. The histopathological classification of ANCA-associated glomerulonephritis is currently evaluated in light of data coming out of a large international validation study. In our continuous search for biomarkers to predict clinical outcome, promising new markers are important subjects of current research. Over the last 2 decades, a host of clinical trials have provided evidence for refinement of therapeutic regimens. We give an overview of clinical trials currently under development, and consider refractory vasculitis in detail. The goal of EUVAS is to stimulate ongoing research in clinical, serological, and histological management and techniques for patients with systemic vasculitis, with an outlook on the applicability for clinical trials.

KW - ANCA

KW - renal outcome

KW - therapy

KW - vasculitis

U2 - 10.1016/j.ekir.2017.09.008

DO - 10.1016/j.ekir.2017.09.008

M3 - Article

VL - 2

SP - 1018

EP - 1031

JO - Kidney International Reports

JF - Kidney International Reports

SN - 2468-0249

IS - 6

ER -